Alzheimer's Disease Against A Cancer

Alzheimer's Disease Against A Cancer.
Although a swat in 2012 suggested a cancer dull could reverse the thinking and memory problems associated with Alzheimer's disease, three groups of researchers now reply they have been unable to duplicate those findings. The teams said their digging could have serious implications for patient safety since the drug involved in the study, bexarotene (Targretin), has humourless side effects, such as major blood-lipid abnormalities, pancreatitis, headaches, fatigue, weight gain, depression, nausea, vomiting, constipation and rash bowtrolprobiotic. "Anecdotally, we have all heard that physicians are treating their Alzheimer's patients with bexarotene, a cancer stimulant with uncompromising side effects," said study co-author Robert Vassar, a professor of cubicle and molecular biology at Northwestern University Feinberg School of Medicine, in Chicago.

This study should be ended immediately, given the failure of three independent research groups to replicate the plaque-lowering property of bexarotene. The US Food and Drug Administration approved bexarotene in 1999 to survey refractory cutaneous T-cell lymphoma acne free. Once approved, however, the pharmaceutical also was available by prescription for "off-label" uses.

The 2012 study suggested that bexarotene was able to in a trice reverse the build-up of beta amyloid plaques in the brains of mice. The authors of the commencing study concluded that treatment with the drug might reverse the cognitive and memory problems associated with the expansion of Alzheimer's. Sangram Sisodia, a professor of neurosciences at the University of Chicago and a study co-author of the news research, admitted being skeptical about the initial findings.

"We were surprised and excited - even stunned - when we blue ribbon saw these results presented at a small conference," Sisodia said in a University of Chicago Medical Center story release. "The mechanism of action made some sense, but the confirmation that they could reduce the areas of plaque by 50 percent within three days and by 75 percent in two weeks seemed too edible to be true".

In attempting to duplicate the findings, the research teams found that they were as a matter of fact too good to be true. "We all went back to our labs and tried to confirm these promising findings. We repeated the opening experiments - a standard process in science. Combined results are really substantial in this field.

None of us found anything like what they described in the 2012 paper". Researchers at the University of Chicago, Northwestern University, Massachusetts General Hospital, Washington University in St Louis and the University of Tubingen in Germany reported in the May 24, 2013 copy of the paper Science that they did not find any reduction in beta amyloid plaques during or after therapy with bexarotene in three different strains of mice. Bexarotene has never been tested on commonalty as a treatment for Alzheimer's disease worldplusmed.net. Currently, there is no cure or effective treatment for the liberal condition, which affects an estimated 5,3 million Americans.